1. "Hematologic Malignancies Research"
Formats
  1. Journal Article (1521)
  2. Meeting Abstract (1232)
  3. Review (76)
  4. Editorial (34)
  5. Book Section (32)
  6. Research Letter (25)
  7. Conference Paper (15)
  8. Correspondence (7)
  9. Guidelines (4)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (2950)
  2. Hematologic Malignancies Research (2950)
  3. GSK Faculty (2412)
  4. Department of Medicine (2277)
  5. Hematologic Malignancies, Division of (2078)
  6. Sloan Kettering Institute Faculty (2026)

More Groups

People
  1. Michel Sadelain (582)
  2. David Scheinberg (499)
  3. Alexander Lesokhin (363)
  4. Carl Landgren (336)
  5. Renier Brentjens (286)
  6. Gabriela Chiosis (279)

More People

Years
  1. 2025 (32)
  2. 2024 (108)
  3. 2023 (175)
  4. 2022 (126)
  5. 2021 (154)
  6. 2020 (173)

More Years

Publications
  1. Blood (636)
  2. Cancer Research (117)
  3. Journal of Clinical Oncology (108)
  4. Clinical Lymphoma, Myeloma and Leukemia (84)
  5. Biology of Blood and Marrow Transplantation (80)
  6. Molecular Therapy (68)

More Publications

Publishers
  1. American Society of Hematology (674)
  2. Nature Publishing Group (367)
  3. Elsevier Inc. (290)
  4. American Association for Cancer Research (245)
  5. Cell Press (116)
  6. American Society of Clinical Oncology (112)

More Publishers

Results (2950)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Low target antigen expression mediates resistance to BCMA CAR T cell therapy
    Meeting Abstract

    Perica, K.; Nataraj, S.; Sjojstrand, M. L.; Nagel, K.; Pavkovic, E.; Payson, E.; Cuenca, A.; Patel, A.; Chung, D.; Mailankody, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Distinct patterns of CD4+and CD8+ T-cell clonal expansion enable broad clinical responses to pembrolizumab + GVD in patients with relapsed Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Rahman, J.; Ganesan, N.; Shah, G. L.; Noy, A.; Schoder, H.; Yahalom, J.; Kumar, A.; Falchi, L.; Hamlin, P. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-life experience with lenalidomide plus anti-CD20 antibodies for the treatment of patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL)
    Meeting Abstract

    Cassanello, G.; Rivas-Delgado, A.; Luna De Abia, A.; Corona, M.; Luttwak, E.; Okwali, M.; Isgor, I.; Galera, P.; Boardman, A. P.; Caron, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Tissue-specific determinants of the adaptive NK cell response
    Meeting Abstract

    Mujal, A. M.; Owyong, M.; Santosa, E. K.; Wingert, C.; Grassmann, S.; Lau, C. M.; Sun, J. C. Y.
    Journal of Immunology (2023)

    Fulltext@MSK | Save
  • STAT3 operates as a rheostat regulating sensitivity of NK cells to inflammatory cytokines
    Meeting Abstract

    Grassmann, S.; Fan, S.; Kim, R.; Beroshvili, G.; Sun, J. C. Y.
    Journal of Immunology (2023)

    Fulltext@MSK | Save
  • Synthetic dual-costimulation for TCR and TCR-like targeted cell therapies
    Meeting Abstract

    Dobrin, A.; Xie, H.; Perica, K.; Jain, N.; Sadelain, M.; Hamieh, M.
    Human Gene Therapy (2023)

    Fulltext@MSK | Save
  • Design and development of IKZF2 and CK1α dual degraders
    Journal Article

    Miyamoto, D. K.; Curnutt, N. M.; Park, S. M.; Stavropoulos, A.; Kharas, M. G.; Woo, C. M.
    Journal of Medicinal Chemistry (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab in pts with relapsed/ refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies
    Meeting Abstract

    Raab, M. S.; Hanel, M.; Nooka, A. K.; Lesokhin, A. M.; Mohty, M.; Niesvizky, R.; Maisel, C.; Arnulf, B.; Larson, S. M.; Varshavsky-Yanovsky, A. N.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): extended follow up and biweekly administration from the MagnetisMM-3 study
    Meeting Abstract

    Raab, M. S.; Hänel, M.; Mohty, M.; Tomasson, M. H.; Arnulf, B.; Bahlis, N. J.; Prince, H. M.; Niesvizky, R.; Rodríguez-Otero, P.; Martinez-Lopez, J.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple myeloma (RRMM): a subgroup analysis from MagnetisMM-3
    Meeting Abstract

    Raab, M. S.; Hänel, M.; Raje, N.; Leleu, X.; Lesokhin, A.; Mohty, M.; Nooka, A. K.; Leip, E.; Conte, U.; Viqueira, A.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save